cyclases (containing GGDEF domains) and broken down by phosphodiesterases (containing EAL or HD-GYP domains) (22, 23) . The genomes of many bacterial species encode a large number of these proteins; K. pneumoniae strains generally harbor ϳ12 proteins with GGDEF domains, 9 with EAL domains, and 6 with both domains (19) . c-di-GMP in various bacteria stimulates the biosynthesis of adhesins, inhibits motility, and can even modulate antibiotic resistance (22) (23) (24) . Meanwhile, the mammalian host may sense c-di-GMP via the innate immune receptor STING (stimulator of interferon genes) and induce proinflammatory cytokine and chemokine production (25, 26) .
Despite the myriad of c-di-GMP-modifying enzymes encoded by the K. pneumoniae genome, the effects of c-di-GMP on lung pathogenesis or expression of virulence factors (beyond type 3 pili) are unknown. In this study, we leveraged a plasmid system allowing the inducible expression of a c-di-GMP-synthesizing enzyme to demonstrate that high levels of c-di-GMP attenuate K. pneumoniae virulence in the lung and upregulate the expression of both type 3 and type 1 pili. This attenuation of infection of the respiratory tract was abrogated when fim expression was silenced, indicating that, in contrast to the critical role of type 1 pili in the urinary tract, type 1 pilus expression may be detrimental to K. pneumoniae pathogenesis in the lung.
RESULTS
pCMW75 increases the global c-di-GMP concentration in K. pneumoniae TOP52. The K. pneumoniae genome encodes as many as 27 distinct enzymes bearing GGDEF domains, EAL domains, or both that could synthesize or hydrolyze c-di-GMP (19, 27) . As it would be infeasible to inactivate all of these genes, we used an inducible plasmid system to raise global c-di-GMP levels in K. pneumoniae. Plasmid pCMW75 encodes isopropyl-␤-D-1-thiogalactopyranoside (IPTG)-inducible QrgB, a Vibrio harveyi GGDEF protein which synthesizes c-di-GMP and has no further homology to K. pneumoniae proteins (28) . The comparator plasmid pCMW98 encodes QrgB*, an inactive AAEEF mutant that is unable to synthesize c-di-GMP. We transformed pCMW75, pCMW98, or the parent vector, pEVS143, into wild-type K. pneumoniae strain TOP52 and grew these transformants in the presence of kanamycin and IPTG (Table 1) . We developed a liquid chromatography-mass spectrometry (LC-MS) assay, using a known concentration of xanthosine 3=,5=-cyclic monophosphate (c-XMP; not synthesized by bacteria) as an internal standard, to measure the normalized c-di-GMP concentration in K. pneumoniae pellets (Fig. 1) . Wild-type TOP52 bearing the parent vector pEVS143 contained 0.77 ng c-di-GMP/mg bacterial pellet. In contrast, induction of active QrgB in TOP52/pCMW75 resulted in a greater than 30-fold increase in the c-di-GMP concentration relative to that in both TOP52/pEVS143 (P ϭ 0.0002) and TOP52/pCMW98 (containing inactive QrgB*; P ϭ 0.0007). A high c-di-GMP concentration impairs K. pneumoniae TOP52 virulence in the lungs. To assess how K. pneumoniae with a globally high c-di-GMP concentration performs in vivo, we utilized an established preclinical model of K. pneumoniae respiratory tract infection (29) . Overnight, IPTG-induced cultures were grown statically at 37°C and then resuspended in phosphate-buffered saline (PBS), and no differences in bacterial growth or aggregation were observed (data not shown). Intratracheal inoculation with 10 7 CFU of TOP52/pEVS143, TOP52/pCMW75, or TOP52/pCMW98 into wild-type C57BL/6J mice was followed by lung and spleen harvest at 24 h postinfection (hpi). Mice infected with K. pneumoniae containing a high c-di-GMP concentration (TOP52/pCMW75) exhibited lower lung bacterial burdens than mice infected with basal levels of c-di-GMP (TOP52/pEVS143, P Ͻ 0.0001; TOP52/pCMW98, P ϭ 0.0002) ( Fig. 2A) . While spleen bacterial titers (a marker for systemic dissemination) were low in all infected mice, they were significantly lower in mice infected with TOP52/pCMW75 than in mice infected with TOP52/pEVS143 and TOP52/pCMW98 (P Ͻ 0.0001 for both comparisons) (Fig. 2B ). Lungs infected with TOP52/pCMW75 demonstrated less severe histopathology than lungs infected with TOP52/pEVS143 or TOP52/pCMW98, which contained dense, largely neutrophilic, inflammatory infiltrates (Fig. 2C ). These data suggest that K. pneumoniae strains with high c-di-GMP levels are attenuated in murine pneumonia.
Attenuation of K. pneumoniae TOP52 virulence by high c-di-GMP levels is secondary to pathogen-specific changes. The mammalian host can sense and respond to c-di-GMP, along with other cyclic dinucleotides, and thus, it was not clear if the attenuation phenotype observed with TOP52/pCMW75 was a result of c-di-GMP effects on the bacteria or the host (25, 30) . To investigate this, we intratracheally infected mice lacking STING (the host receptor for c-di-GMP) with TOP52/pEVS143 or TOP52/pCMW75. At 24 hpi in both the lungs and spleens, TOP52/pCMW75 was attenuated relative to TOP52/pEVS143 in the STING Ϫ/Ϫ mouse background (P Ͻ 0.0001) (Fig. 3) , similar to its attenuation in wild-type C57BL/6J mice. These data suggest that the decrease in pulmonary virulence with K. pneumoniae containing high c-di-GMP levels reflects the effects of c-di-GMP on the bacteria and not augmented host sensing of the increased c-di-GMP levels. High c-di-GMP levels do not affect K. pneumoniae TOP52 serum resistance or capsule production. The abilities of K. pneumoniae to survive in serum and produce an exopolysaccharide capsule are important for infection of the lung and dissemination (10, 11, 31) . To investigate if increased c-di-GMP levels affect the ability of K. pneumoniae to survive in serum, we performed serum resistance assays with TOP52/ pEVS143, TOP52/pCMW75, and TOP52/pCMW98 along with two control strains. We constructed the negative-control strain TOP52 ΔrfaH, a mutant lacking the antiterminator regulatory factor RfaH, which is important in capsule production and serum resistance (13) . We also used ATCC 43816, a murine-adapted K. pneumoniae strain known to produce abundant capsule and resist serum killing (11, 13) . These assays demonstrated no significant differences in serum survival between TOP52/pCMW75 (P ϭ 0.7532) or TOP52/pCMW98 (P ϭ 0.5344) and TOP52/pEVS143 (Fig. 4A) . As expected, the rate of survival in serum was lower for TOP52 ΔrfaH and higher for ATCC 43816 (P Ͻ 0.0001 for each strain compared to TOP52/pEVS143). To quantify capsule production, we measured the levels of uronic acid, a component of K. pneumoniae capsule, in extracts from the same five strains. Again, no significant differences in uronic acid levels were observed between TOP52/pCMW75 (P ϭ 0.4116) or TOP52/pCMW98 (P ϭ 0.5414) and TOP52/pEVS143 (Fig. 4B) . As expected, TOP52 ΔrfaH (P ϭ 0.0024) and ATCC 43816 (P ϭ 0.0008) produced less and more uronic acid, respectively, than TOP52/pEVS143. Together, these data indicate that high c-di-GMP levels in TOP52/ pCMW75 do not alter capsule production or serum resistance and that these factors do not explain TOP52/pCMW75 attenuation in vivo. High c-di-GMP levels promote type 1 piliation in K. pneumoniae TOP52. c-di-GMP is generally thought to promote the expression of surface adhesins by bacteria. Specifically, in K. pneumoniae, c-di-GMP has been shown to promote type 3 pilus expression via the sensor protein MrkH (18) (19) (20) . Quantitative reverse transcription-PCR (qRT-PCR) for mrkA, the main type 3 pilus subunit, confirmed that type 3 pilus expression is upregulated in TOP52/pCMW75 relative to its expression in TOP52 harboring the vector control (P Ͻ 0.0001) (see Fig. S1A in the supplemental material).
It was unknown whether c-di-GMP influences the regulation of other pilus systems relevant to virulence. In K. pneumoniae (as in Escherichia coli), type 1 pili are transcriptionally regulated by an invertible phase switch, fimS, upstream of the gene encoding the main pilus subunit, fimA. A PCR-based phase assay was used to assess the proportions of K. pneumoniae populations in the phase-on versus phase-off promoter orientations. While TOP52/pEVS143 and TOP52/pCMW98 were almost exclusively phase off after growth in static culture, TOP52/pCMW75, which has high levels of c-di-GMP, displayed a significant phase-on population (Fig. 5A ). As measured by qRT-PCR, TOP52/ pCMW75 exhibited ϳ4-fold increased levels of the fimA transcript relative to those in TOP52/pEVS143 or TOP52/pCMW98 (P Ͻ 0.0001 and P ϭ 0.0003, respectively) ( Fig. 5B ).
FIG 3
A high c-di-GMP concentration attenuates K. pneumoniae TOP52 virulence in STING Ϫ/Ϫ mice. Female STING Ϫ/Ϫ mice were infected with 10 7 CFU of TOP52/pEVS143 or TOP52/pCMW75 (which has high levels of c-di-GMP) by intratracheal inoculation. Lung (A) and spleen (B) bacterial loads were quantified at 24 hpi. Data were combined from 5 independent experiments. Each symbol represents the result for one animal, short bars represent the geometric mean for each group, and full dotted horizontal lines represent the limits of detection. ***, P Ͻ 0.001, Mann-Whitney U test.
FIG 4
A high c-di-GMP concentration does not affect K. pneumoniae TOP52 serum resistance or capsule production. (A) In serum resistance assays, bacterial strains were incubated with pooled human active serum for 3 h; bacterial survival is expressed as a percentage of the input number of CFU. (B) Capsule extraction and quantification of the capsule component uronic acid were performed on the indicated strains. Data were combined from at least 3 independent experiments, and the results are shown as the means Ϯ SEMs. #, survival was Ͻ0.01%. P values were determined by the Mann-Whitney U test. **, P Ͻ 0.01; ***, P Ͻ 0.001.
c-di-GMP Effects on Klebsiella Virulence
Infection and Immunity
To confirm that high c-di-GMP levels influenced the actual production of type 1 pili in K. pneumoniae, we performed immunoblots for FimA. With the standard exposure, a significant FimA band was evident for TOP52/pCMW75, but the band was difficult to visualize for the TOP52/pEVS143 and TOP52/pCMW98 controls (Fig. 5C ). Relative quantification of the band intensity after prolonged blot exposure demonstrated significantly increased FimA levels in TOP52/pCMW75 compared to TOP52/pEVS143 or TOP52/pCMW98 (P Ͻ 0.0001 and P ϭ 0.0015, respectively) (Fig. 5D ). In total, these data argue that, besides type 3 pili, a high c-di-GMP concentration also promotes the production of type 1 pili in K. pneumoniae TOP52.
c-di-GMP promotion of type 1 pilus production is not mediated by MrkH. MrkH features a PilZ domain which can sense c-di-GMP and, in turn, bind to the mrkA promoter, resulting in the transcriptional activation of type 3 pili (18, 19) . Given the novel finding that c-di-GMP also promotes type 1 pilus production in K. pneumoniae, we asked whether this upregulation was also mediated via MrkH. We deleted mrkH in strain TOP52 and assessed type 1 pilus expression in the setting of high c-di-GMP concentrations. The c-di-GMP concentration was confirmed to be higher in TOP52 ΔmrkH/ pCMW75 than in the control strains TOP52 ΔmrkH/pCMW98 and TOP52 ΔmrkH/ pEVS143 when measured by LC-MS (data not shown). Of note, qRT-PCR did demonstrate the upregulation of mrkA in TOP52 ΔmrkH/pCMW75, although it was not nearly to the extent to which mrkA was upregulated in TOP52/pCMW75 (Fig. S1 ). These data indicate that while MrkH is the primary mediator of c-di-GMP signaling leading to type 3 pilus production, type 3 pili are also regulated by c-di-GMP via MrkHindependent mechanisms. Consistent with prior reports (32, 33) , decreased type 3 pilus production in TOP52 ΔmrkH was associated with increased type 1 piliation relative to that in wild-type K. pneumoniae. While the sizes of the fimS phase-on populations were appreciable in all TOP52 ΔmrkH transformants, the size of the phase-on population of TOP52 ΔmrkH/ pCMW75 was increased compared to that for the controls (Fig. 6A) . In addition, qRT-PCR of TOP52 ΔmrkH/pCMW75 demonstrated increased amounts of the fimA transcript relative to those for TOP52 ΔmrkH/pEVS143 or TOP52 ΔmrkH/pCMW98 P Ͻ 0.0001 for both comparisons (Fig. 6B) . While FimA bands were evident for all TOP52 ΔmrkH transformants, immunoblots demonstrated increased production of FimA in TOP52 ΔmrkH/pCMW75 compared to TOP52 ΔmrkH/pEVS143 or TOP52 ΔmrkH/pCMW98 (P ϭ 0.0002 and P ϭ 0.0207, respectively) ( Fig. 6C and D) . These data indicate that increases in type 1 pilus production triggered by high c-di-GMP concentrations are not mediated by MrkH.
Increased expression of type 1 pili, but not type 3 pili, is detrimental for K. pneumoniae TOP52 virulence in the lung. To determine if the increased production of type 1 or type 3 pili contributed to the attenuated virulence of K. pneumoniae strains with high-c-di-GMP levels in the lung, we constructed mutant strains unable to produce Fig. 7A and B) . In contrast, infection with TOP52 ΔmrkA/pCMW75 maintained significant reductions in lung and spleen bacterial burdens at 24 hpi relative to the burdens of TOP52 ΔmrkA/pEVS143 (P Ͻ 0.0001 and P ϭ 0.0004, respectively) ( Fig. 7C and D) . The failure of high c-di-GMP levels to attenuate pneumonia in the absence of type 1 pili but not in the absence of type 3 pili indicates that the increased production of type 1 pili in the lung may hamper K. pneumoniae virulence in this niche.
DISCUSSION
In the face of accelerating antimicrobial resistance in K. pneumoniae, additional therapeutic targets are needed. The present work is the first to examine the influence of c-di-GMP on K. pneumoniae pulmonary virulence. These murine experiments suggest that K. pneumoniae in a state with high c-di-GMP levels is less virulent in the lung.
FIG 7
A high c-di-GMP concentration attenuates K. pneumoniae TOP52 virulence in the absence of type 3 pili but not in the absence of type 1 pili. Female C57BL/6J mice were infected with 10 7 CFU of TOP52 ΔfimS-K/pEVS143, TOP52 ΔfimS-K/pCMW75 (which has high levels of c-di-GMP), TOP52 ΔmrkA/pEVS143, or TOP52 ΔmrkA/pCMW75 (which has high levels of c-di-GMP) by intratracheal inoculation. Lung (A, C) and spleen (B, D) bacterial loads were quantified at 24 hpi. Data were combined from at least 3 independent experiments. Each symbol represents one animal, short bars represent the geometric mean for each group, and full dotted horizontal lines represent limits of detection. ***, P Ͻ 0.001, MannWhitney U test.
Manipulation of c-di-GMP synthetic and degradative pathways in pathogenic bacteria may thus represent a promising means of targeting virulence. Efforts are under way to synthesize and develop small-molecule broad-EAL-domain inhibitors that could alter a pathogen's ability to cleave c-di-GMP (34, 35) . It should be noted that while high c-di-GMP levels attenuated K. pneumoniae infection in the lung, this state may not be detrimental for pathogenesis in other niches. For example, one could postulate that increased type 1 piliation triggered by high c-di-GMP levels might augment K. pneumoniae virulence in the urinary tract; ongoing studies will address such questions.
Our experiments relied on the elevated c-di-GMP concentrations achieved via expression of a diguanylate cyclase enzyme in trans, and our controls (the QrgB* mutant) helped to ensure that the QrgB protein itself was not exerting off-target effects. This system may not, however, reflect the differential functions of apparently redundant c-di-GMP-modifying enzymes in K. pneumoniae or the potential temporal and spatial regulation of c-di-GMP synthesis within the cell (22, 36) . Thus, natural perturbations in c-di-GMP levels may have different effects on virulence factors downstream. Additionally, while we suggest that high c-di-GMP levels result in a K. pneumoniae virulence profile that is attenuated in initial infection of the lung, the effects of the perpetual induction of high c-di-GMP levels over the course of a longer infection have not been investigated.
In our focused analyses, we demonstrated that both type 1 and type 3 pilus adhesins are upregulated in the setting of high c-di-GMP levels, whereas capsule expression did not seem to be significantly affected. However, c-di-GMP is a ubiquitous second messenger and, as such, could impart numerous downstream effects in K. pneumoniae and other bacteria; transcriptional profiling and other unbiased approaches may help to further define these in future work. Regardless of the mechanism, however, if the phenotypes observed in the present model extend to other K. pneumoniae strains or additional lung pathogens, then c-di-GMP pathways remain attractive therapeutic targets.
Of additional note, c-di-GMP has been shown to stimulate the innate immune system in mice and has even been proposed to be a vaccine adjuvant (30, 37) . However, the levels of c-di-GMP used in studies showing host-protective innate immune effects were ϳ10,000-fold higher than the level contained in our intratracheal inocula. Additionally, the persistence of the attenuated K. pneumoniae phenotype with high c-di-GMP levels in STING Ϫ/Ϫ mice suggests that the effects on virulence in this study were not host mediated.
This work begins to illustrate the complexity of interactions between type 1 pili, type 3 pili, and c-di-GMP in K. pneumoniae. For example and as previously reported (33, 34) , the loss of type 3 pili results in increased type 1 pilus production through regulatory mechanisms that remain unclear. Furthermore, while c-di-GMP promotes increased expression of each adhesin, for type 3 pili, this is mediated by both MrkH-dependent and MrkH-independent effects, while type 1 pili exhibit only MrkH-independent regulation. The specific mechanism by which c-di-GMP exerts its effects on these fimbrial operons in the absence of MrkH remains to be identified.
In conclusion, c-di-GMP promotes the expression of both type 1 and type 3 pili in K. pneumoniae while attenuating virulence in the lung. Further efforts addressing c-di-GMP pathways as a means of thwarting pathogenesis in vivo are warranted.
MATERIALS AND METHODS
Bacterial strains, plasmids, and culture conditions. The K. pneumoniae strains and plasmids used in this study are shown in Table 1 . Growth curves measuring the optical density at 600 nm (OD 600 ) over time, as well as confirmation by plating at multiple time points, demonstrated no significant differences in growth among the strains used (data not shown). For all experiments, including those involving murine infections, and unless otherwise specified, bacteria were prepared by growing them statically in 20-ml cultures at 37°C for 16 h in Luria-Bertani (LB) broth. When pEVS143, pCMW75, or pCMW98 was present, 50 g/ml kanamycin and 0.5 mM IPTG were also added at culture onset. For murine experiments, bacteria were centrifuged at 8,000 ϫ g for 10 min, resuspended in sterile PBS, and diluted to the desired inoculum concentration by measuring the OD 600 . The inocula were verified by serial dilution and plating.
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Bacterial mutagenesis. Bacteriophage lambda Red recombinase mutagenesis was modified for use with K. pneumoniae as previously described (13) . Briefly, bacteria containing pKD46s were grown with shaking overnight at 30°C with 50 g/ml spectinomycin and 0.7% arabinose in LB broth, subcultured 1:100, and grown to an OD 600 of 0.5 to 0.6. Cells were transformed with a kanamycin resistance determinant flanked by sequences with homology to the target gene (the primers are listed in Table 2 ) and recovered overnight in superoptimal broth containing 20 mM glucose (SOC medium). Colonies were selected on LB agar containing 50 g/ml kanamycin. The kanamycin resistance gene was excised by transforming the cells with temperature-sensitive plasmid pCP20 carrying the FLP recombinase. Clones were verified by direct sequencing.
Quantification of c-di-GMP. Measurements were performed using an LC-MS method (38) with addition of an internal standard for the absolute quantification of the c-di-GMP concentration (expressed as the amount per milligram of bacterial pellet). Briefly, 4 ml of bacterial cultures was pelleted, and the pellet was weighed and homogenized in 500 l water containing 100 ng of c-XMP (Sigma-Aldrich, St. Louis, MO) using an Omni Bead Ruptor 24 apparatus (Omni International, Kennesaw, GA). After centrifugation of the homogenized liquids, the supernatants were analyzed by LC-MS alongside calibration samples of cyclic di-GMP containing 100 ng of c-XMP. LC-MS analysis was performed with a Shimadzu 20AD high-performance liquid chromatography system and a Leap PAL autosampler coupled to a triple-quadrupole mass spectrometer (API 4000; Applied Biosystems, Foster City, CA) operated in the multiple-reaction-monitoring mode. The positive-ion electrospray ionization mode was used for detection of both c-di-GMP and c-XMP. Study samples were injected in duplicate in each independent experiment. Data were processed with Analyst (version 1.5.1) software (Applied Biosystems).
Mouse infections, organ titers, and histology. All animal procedures were approved by the Institutional Animal Care and Use Committee at Washington University School of Medicine. Female C57BL/6J and C57BL/6J-Tmem173 gt /J (STING Ϫ/Ϫ ) mice (The Jackson Laboratory, Bar Harbor, ME) aged 7 to 8 weeks were intratracheally inoculated as previously described (39) . Briefly, each mouse was anesthetized with inhaled isoflurane, and the trachea was exposed via surgical dissection. The inoculum (20 l containing 1 ϫ 10 7 to 2 ϫ 10 7 CFU) was injected intratracheally using a 30-gauge, caudally directed needle. The skin was closed using Vetbond tissue adhesive (3M Animal Care Products, St. Paul, MN). Mice received 1 mg/kg of body weight sustained-release buprenorphine subcutaneously for pain control. To determine the bacterial burden at 24 hpi, the animals were sacrificed and their organs (lungs, spleens) were homogenized in sterile PBS by use of a Bullet Blender homogenizer (Next Advance, Averill Park, NY) for 5 min; aliquots were serially diluted and plated. Organs that were removed for histology were washed in PBS, fixed in 10% neutral buffered formalin, dehydrated in ethanol, and paraffin embedded; 5-m sections were stained with hematoxylin and eosin. Micrographs were obtained using an Olympus DP25 camera and a BX40 light microscope.
Serum resistance. Serum bactericidal assays were adapted from those previously described (40) . Blood was drawn by venipuncture from healthy adult donors according to a protocol approved by the Human Research Protection Office at Washington University. Briefly, 25 l of statically grown bacteria (10 6 CFU/ml in PBS) was mixed in 96-well microplates with 75 l of pooled human serum, and the mixture was incubated for 3 h at 37°C. Samples were serially diluted and plated to calculate percent survival (ratio of the number of CFU at 3 h to the input number of CFU).
Capsule quantification. Capsule extraction and uronic acid quantification were performed using a modified protocol (41, 42) . Five hundred microliters of overnight static LB cultures was mixed with 100 l of 1% Zwittergent 3-14 (Sigma-Aldrich) in 100 mM citric acid, and the mixture was incubated at 50°C for 20 min. Following centrifugation, the supernatants were precipitated with 1 ml cold ethanol. After recentrifugation, the pellet was dissolved in 200 l water and 1.2 ml of 12.5 mM tetraborate in concentrated H 2 SO 4 was added. Samples were vortexed, boiled at 95°C for 5 min, and mixed with 20 l of 0.15% 3-hydroxydiphenol (Sigma-Aldrich) in 0.5% NaOH. The absorbance at 520 nm was measured. The uronic acid concentration in each sample was determined from a standard curve of glucuronic acid (Sigma-Aldrich).
Phase assay for type 1 pili. To determine the orientation of the fimS phase switch in K. pneumoniae, a phase assay was adapted as previously described (15) . PCR primers (Table 2) were used to amplify an 817-bp DNA region including fimS, and the PCR product was digested with HinfI (New England BioLabs, Ipswich, MA). A phase-on switch yields products of 605 and 212 bp, and a phase-off switch yields products of 496 and 321 bp.
Quantitative reverse transcription PCR. qRT-PCR was performed as previously described, and the amounts of the PCR products were normalized to those of a K. pneumoniae housekeeping gene, rpoB (43) . The cultures were grown overnight with antibiotics, as appropriate, subcultured 1:100 with antibiotics and inducing agents, and grown to an OD 600 of 0.4 to 0.6. mRNA was isolated using an RNeasy minikit (Qiagen, Germantown, MD). cDNA was synthesized with an iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) using a C1000 Touch thermal cycler (Bio-Rad). qRT-PCR was performed with SsoAdvanced Universal SYBR green Supermix (Bio-Rad) and the primers listed in Table 2 using an ABI 7500 real-time PCR system (Applied Biosystems).
Immunoblots. Acid-treated whole-cell immunoblotting was performed as previously described (44) using 1:2,000 rabbit anti-type 1 pilus (45) and 1:500,000 rabbit anti-GroEL (Sigma-Aldrich) primary antibodies. Amersham ECL horseradish peroxidase-linked donkey anti-rabbit IgG (GE Healthcare, Buckinghamshire, UK) secondary antibody (1:2,000) was applied, followed by application of Clarity enhanced chemiluminescence (ECL) substrate (Bio-Rad), and the membrane was developed using GeneMate blue autoradiography film (BioExpress, Kaysville, UT). Relative band intensities were quantified using ImageJ software (http://rsb.info.nih.gov/ij/). All primers are listed in the 5=-3= orientation.
c-di-GMP Effects on Klebsiella Virulence Infection and Immunity
Statistical analysis.
Comparisons between two groups of continuous variables were analyzed using the nonparametric Mann-Whitney U test. All tests were two-tailed, and P values of Ͻ0.05 were considered significant. Analyses were performed using GraphPad Prism (version 7.01) software.
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